What is BFHIV's earnings per share (EPS)?

BFHIV (BFHIV) reported diluted earnings per share of $10.89 for fiscal year 2025. This represents a 98.4% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

BFHIV Financials

BFHIV

Source SEC Filings (10-K/10-Q) Updated Mar 31, 2026 Currency USD FYE December

This page shows BFHIV (BFHIV) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 18 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI BFHIV FY2025 2026-04-22

Flat revenue masks a balance-sheet repair story, with cash-rich operations funding debt reduction and a wider equity cushion.

From FY2023 to FY2025, revenue moved down from $4.3B to $3.8B rather than compounding upward. Even so, operating cash flow improved to $2.1B as long-term debt fell to $4.3B, showing the company strengthened itself mainly through cash generation and liability reduction rather than sales growth.

By FY2025, liabilities still funded about 85.3% of assets, so this remains a balance-sheet-driven model rather than a lightly financed one. The important change is that cash stayed near $3.6B even as long-term debt fell to $4.3B, which means the stronger equity cushion came from internal cash generation, not a scramble for liquidity.

Net income recovered to $518M in FY2025 despite almost no revenue growth, so the earnings rebound was not really a sales story. Instead, a lower interest burden of $854M and slightly lower overhead of $2.0B did much of the work, making reported profit more sensitive to financing and cost discipline than to top-line movement.

Financial Health Signals

Financial Profile 30/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of BFHIV's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Growth

BFHIV's revenue grew a modest 0.2% year-over-year to $3.8B. This slow but positive growth earns a score of 24/100.

Leverage

BFHIV carries a low D/E ratio of 1.29, meaning only $1.29 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 76/100, indicating a strong balance sheet with room for future borrowing.

Returns

BFHIV's ROE of 15.6% shows moderate profitability relative to equity, earning a score of 45/100. This is up from 9.1% the prior year.

Piotroski F-Score Strong

7/9

BFHIV passes 7 of 9 financial strength tests. All 4 profitability signals pass (positive income, cash flow, and earnings quality), all 2 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Cash-Backed

4.04x

For every $1 of reported earnings, BFHIV generates $4.04 in operating cash flow ($2.1B OCF vs $518.0M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$3.8B

YoY+0.2%

5Y CAGR+3.1%

10Y CAGR-5.0%

BFHIV generated $3.8B in revenue in fiscal year 2025. This represents an increase of 0.2% from the prior year.

EBITDA

N/A

Net Income

$518.0M

YoY+87.0%

5Y CAGR+19.3%

10Y CAGR-1.5%

BFHIV reported $518.0M in net income in fiscal year 2025. This represents an increase of 87.0% from the prior year.

EPS (Diluted)

$10.89

YoY+98.4%

5Y CAGR+19.5%

10Y CAGR+2.1%

BFHIV earned $10.89 per diluted share (EPS) in fiscal year 2025. This represents an increase of 98.4% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$3.6B

YoY-2.0%

5Y CAGR+5.2%

10Y CAGR+11.9%

BFHIV held $3.6B in cash against $4.3B in long-term debt as of fiscal year 2025.

Dividends Per Share

$0.86

YoY+2.4%

5Y CAGR-7.4%

BFHIV paid $0.86 per share in dividends in fiscal year 2025. This represents an increase of 2.4% from the prior year.

Shares Outstanding

43M

YoY-12.2%

BFHIV had 43M shares outstanding in fiscal year 2025. This represents a decrease of 12.2% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

13.5%

YoY+6.2pp

5Y CAGR+7.0pp

10Y CAGR+4.1pp

BFHIV's net profit margin was 13.5% in fiscal year 2025, showing the share of revenue converted to profit. This is up 6.2 percentage points from the prior year.

Return on Equity

15.6%

YoY+6.5pp

5Y CAGR+1.5pp

10Y CAGR-14.6pp

BFHIV's ROE was 15.6% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 6.5 percentage points from the prior year.

Capital Allocation

R&D Spending

N/A

Share Buybacks

$313.0M

YoY+469.1%

10Y CAGR-10.5%

BFHIV spent $313.0M on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding. This represents an increase of 469.1% from the prior year.

Capital Expenditures

N/A

BFHIV Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$3.8B+0.2%	$3.8B-10.5%	$4.3B+12.1%	$3.8B+16.9%	$3.3B-0.8%	$3.3B
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	$2.1B
Gross Profit	N/A	N/A	N/A	N/A	N/A	$1.2B
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	$2.0B-3.5%	$2.1B-1.5%	$2.1B+168.5%	$779.0M+16.1%	$671.0M+534.8%	$105.7M
Operating Income	N/A	N/A	N/A	N/A	N/A	$301.0M
Interest Expense	$854.0M-11.0%	$960.0M+9.2%	$879.0M+74.8%	$503.0M+31.3%	$383.0M-23.2%	$499.0M
Income Tax	$94.0M-7.8%	$102.0M-55.8%	$231.0M+203.9%	$76.0M-69.2%	$247.0M+165.6%	$93.0M
Net Income	$518.0M+87.0%	$277.0M-61.4%	$718.0M+222.0%	$223.0M-72.2%	$801.0M+274.3%	$214.0M
EPS (Diluted)	$10.89+98.4%	$5.49-61.7%	$14.34+221.5%	$4.46-72.2%	$16.02+259.2%	$4.46

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	$1.0B+4.4%	$975.0M+0.4%	$971.0M+4.5%	$929.0M-4.2%	$970.0M+4.9%	$925.0M-5.9%	$983.0M+4.7%	$939.0M
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	$472.0M-14.8%	$554.0M+16.4%	$476.0M-1.0%	$481.0M+0.8%	$477.0M-10.8%	$535.0M-6.8%	$574.0M+22.4%	$469.0M
Operating Income	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	$193.0M-3.0%	$199.0M-5.2%	$210.0M-4.5%	$220.0M-2.2%	$225.0M-2.6%	$231.0M-3.8%	$240.0M-0.4%	$241.0M
Income Tax	$62.0M+1650.0%	-$4.0M-150.0%	$8.0M-77.1%	$35.0M-36.4%	$55.0M+257.1%	-$35.0M-194.6%	$37.0M-21.3%	$47.0M
Net Income	$181.0M+241.5%	$53.0M-71.8%	$188.0M+35.3%	$139.0M+0.7%	$138.0M+1625.0%	$8.0M+300.0%	$2.0M-98.5%	$133.0M
EPS (Diluted)	$4.15	N/A	$3.96+34.7%	$2.94+5.8%	$2.78	N/A	$0.05-98.1%	$2.66

BFHIV Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$22.7B-1.0%	$22.9B-1.1%	$23.1B-8.9%	$25.4B+16.8%	$21.7B-3.6%	$22.5B
Current Assets	N/A	N/A	N/A	N/A	N/A	$19.6B
Cash & Equivalents	$3.6B-2.0%	$3.7B+2.5%	$3.6B-7.7%	$3.9B+27.7%	$3.0B+8.9%	$2.8B
Inventory	N/A	N/A	N/A	N/A	N/A	$164.3M
Accounts Receivable	$148.0M+2.1%	$145.0M+0.7%	$144.0M-12.2%	$164.0M+8.6%	$151.0M-60.7%	$383.8M
Goodwill	$634.0M0.0%	$634.0M0.0%	$634.0M0.0%	$634.0M0.0%	$634.0M0.0%	$634.0M
Total Liabilities	$19.3B-2.5%	$19.8B-1.9%	$20.2B-12.6%	$23.1B+17.7%	$19.7B-6.5%	$21.0B
Current Liabilities	N/A	N/A	N/A	N/A	N/A	$10.4B
Long-Term Debt	$4.3B-22.5%	$5.6B+5.0%	$5.3B-33.9%	$8.0B+7.6%	$7.4B+165.1%	$2.8B
Total Equity	$3.3B+9.0%	$3.1B+4.6%	$2.9B+28.8%	$2.3B+8.6%	$2.1B+37.1%	$1.5B
Retained Earnings	$1.5B+47.6%	$999.0M+30.2%	$767.0M+724.7%	$93.0M+206.9%	-$87.0M-101.8%	$4.8B

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$22.3B-1.6%	$22.7B+4.4%	$21.7B-0.5%	$21.8B-2.5%	$22.4B-2.2%	$22.9B+5.3%	$21.7B-1.8%	$22.1B
Current Assets	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cash & Equivalents	$3.6B+0.9%	$3.6B-4.3%	$3.8B-0.9%	$3.8B-9.8%	$4.2B+14.5%	$3.7B+6.6%	$3.5B-14.9%	$4.1B
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	$148.0M	N/A	N/A	N/A	$145.0M	N/A	N/A
Goodwill	N/A	$634.0M	N/A	N/A	N/A	$634.0M	N/A	N/A
Total Liabilities	$19.0B-1.8%	$19.3B+5.1%	$18.4B-1.4%	$18.7B-3.4%	$19.3B-2.7%	$19.8B+6.5%	$18.6B-1.8%	$19.0B
Current Liabilities	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Long-Term Debt	N/A	$4.3B+13.8%	$3.8B-10.4%	$4.2B-17.5%	$5.1B-7.8%	$5.6B+21.2%	$4.6B	N/A
Total Equity	$3.3B-0.1%	$3.3B+0.3%	$3.3B+4.8%	$3.2B+3.2%	$3.1B+0.6%	$3.1B-2.0%	$3.1B-1.8%	$3.2B
Retained Earnings	$1.6B+11.4%	$1.5B+3.0%	$1.4B+14.1%	$1.3B+11.5%	$1.1B+12.7%	$999.0M-0.4%	$1.0B-0.9%	$1.0B

BFHIV Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	$2.1B+12.5%	$1.9B-6.4%	$2.0B+7.5%	$1.8B+19.8%	$1.5B-18.1%	$1.9B
Capital Expenditures	N/A	N/A	N/A	$68.0M-19.0%	$84.0M+55.6%	$54.0M
Free Cash Flow	N/A	N/A	N/A	$1.8B+22.0%	$1.5B-20.2%	$1.8B
Investing Cash Flow	-$1.4B-17.3%	-$1.2B-248.4%	$788.0M+115.4%	-$5.1B-202.2%	-$1.7B-195.3%	$1.8B
Financing Cash Flow	-$807.0M-36.3%	-$592.0M+80.8%	-$3.1B-194.5%	$3.3B+437.3%	$608.0M+114.6%	-$4.2B
Dividends Paid	$40.0M-7.0%	$43.0M+2.4%	$42.0M-2.3%	$43.0M+2.4%	$42.0M-31.1%	$61.0M
Share Buybacks	$313.0M+469.1%	$55.0M+57.1%	$35.0M+191.7%	$12.0M	$0	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	$487.0M-14.3%	$568.0M-6.1%	$605.0M+15.0%	$526.0M+33.8%	$393.0M-18.0%	$479.0M+5.0%	$456.0M-4.4%	$477.0M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	$317.0M+121.1%	-$1.5B-344.7%	-$338.0M-52.9%	-$221.0M-132.0%	$691.0M+151.1%	-$1.4B-137.4%	-$569.0M-1935.5%	$31.0M
Financing Cash Flow	-$475.0M-160.6%	$784.0M+356.2%	-$306.0M+57.7%	-$723.0M-28.6%	-$562.0M-150.4%	$1.1B+328.5%	-$488.0M-100.0%	-$244.0M
Dividends Paid	$10.0M0.0%	$10.0M0.0%	$10.0M0.0%	$10.0M0.0%	$10.0M-9.1%	$11.0M+10.0%	$10.0M-9.1%	$11.0M
Share Buybacks	$153.0M+24.4%	$123.0M+207.5%	$40.0M-14.9%	$47.0M-54.4%	$103.0M+134.1%	$44.0M	$0	$0

BFHIV Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	37.0%
Operating Margin	N/A	N/A	N/A	N/A	N/A	9.1%
Net Margin	13.5%+6.2pp	7.2%-9.5pp	16.7%+10.9pp	5.8%-18.6pp	24.5%+18.0pp	6.5%
Return on Equity	15.6%+6.5pp	9.1%-15.5pp	24.6%+14.8pp	9.8%-28.5pp	38.4%+24.3pp	14.1%
Return on Assets	2.3%+1.1pp	1.2%-1.9pp	3.1%+2.2pp	0.9%-2.8pp	3.7%+2.7pp	0.9%
Current Ratio	N/A	N/A	N/A	N/A	N/A	1.88
Debt-to-Equity	1.29-0.5	1.820.0	1.81-1.7	3.54-0.0	3.57+1.7	1.84
FCF Margin	N/A	N/A	N/A	46.5%+1.9pp	44.6%-10.9pp	55.5%

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	17.8%+12.3pp	5.4%-13.9pp	19.4%+4.4pp	15.0%+0.7pp	14.2%+13.4pp	0.9%+0.7pp	0.2%-14.0pp	14.2%
Return on Equity	5.4%+3.8pp	1.6%-4.1pp	5.7%+1.3pp	4.4%-0.1pp	4.5%+4.2pp	0.3%+0.2pp	0.1%-4.1pp	4.2%
Return on Assets	0.8%+0.6pp	0.2%-0.6pp	0.9%+0.2pp	0.6%+0.0pp	0.6%+0.6pp	0.0%+0.0pp	0.0%-0.6pp	0.6%
Current Ratio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Debt-to-Equity	5.71+4.4	1.29+0.2	1.14-0.2	1.34-0.3	1.67-0.2	1.82+0.3	1.47-4.5	5.99
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Frequently Asked Questions

What is BFHIV's annual revenue?

BFHIV (BFHIV) reported $3.8B in total revenue for fiscal year 2025. This represents a 0.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is BFHIV's revenue growing?

BFHIV (BFHIV) revenue grew by 0.2% year-over-year, from $3.8B to $3.8B in fiscal year 2025.

Is BFHIV profitable?

Yes, BFHIV (BFHIV) reported a net income of $518.0M in fiscal year 2025, with a net profit margin of 13.5%.

How much debt does BFHIV have?

As of fiscal year 2025, BFHIV (BFHIV) had $3.6B in cash and equivalents against $4.3B in long-term debt.

What is BFHIV's net profit margin?

BFHIV (BFHIV) had a net profit margin of 13.5% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

Does BFHIV pay dividends?

Yes, BFHIV (BFHIV) paid $0.86 per share in dividends during fiscal year 2025.

What is BFHIV's return on equity (ROE)?

BFHIV (BFHIV) has a return on equity of 15.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is BFHIV's operating cash flow?

BFHIV (BFHIV) generated $2.1B in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are BFHIV's total assets?

BFHIV (BFHIV) had $22.7B in total assets as of fiscal year 2025, including both current and long-term assets.

Does BFHIV buy back shares?

Yes, BFHIV (BFHIV) spent $313.0M on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

How many shares does BFHIV have outstanding?

BFHIV (BFHIV) had 43M shares outstanding as of fiscal year 2025.

What is BFHIV's debt-to-equity ratio?

BFHIV (BFHIV) had a debt-to-equity ratio of 1.29 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is BFHIV's return on assets (ROA)?

BFHIV (BFHIV) had a return on assets of 2.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is BFHIV's Piotroski F-Score?

BFHIV (BFHIV) has a Piotroski F-Score of 7 out of 9, indicating strong financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are BFHIV's earnings high quality?

BFHIV (BFHIV) has an earnings quality ratio of 4.04x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is BFHIV?

BFHIV (BFHIV) scores 30 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.